Liposomal Amphotericin B as Initial Therapy for Invasive Mold Infection: A Randomized Trial Comparing a High-Loading Dose Regimen with Standard Dosing (AmBiLoad Trial)-Reference-Cited by-同舟云学术

Liposomal Amphotericin B as Initial Therapy for Invasive Mold Infection: A Randomized Trial Comparing a High-Loading Dose Regimen with Standard Dosing (AmBiLoad Trial)

Published:2007-05-15 Issue:10 Volume:44 Page:1289-1297
ISSN:1058-4838
Container-title:Clinical Infectious Diseases
language:en
Short-container-title:Clinical Infectious Diseases

Author:

Cornely O. A.,Maertens J.,Bresnik M.,Ebrahimi R.,Ullmann A. J.,Bouza E.,Heussel C. P.,Lortholary O.,Rieger C.,Boehme A.,Aoun M.,Horst H.-A.,Thiebaut A.,Ruhnke M.,Reichert D.,Vianelli N.,Krause S. W.,Olavarria E.,Herbrecht R.,

Publisher

Oxford University Press (OUP)

Subject

Infectious Diseases,Microbiology (medical)

Link

http://academic.oup.com/cid/article-pdf/44/10/1289/1016109/44-10-1289.pdf

Reference21 articles.

1. Changing patterns and trends in systemic fungal infections

2. Epidemiology and Outcome of Mould Infections in Hematopoietic Stem Cell Transplant Recipients

3. Aspergillus Infections in Transplant Recipients

4. Voriconazole: A New Triazole Antifungal Agent

5. Efficacy and Safety of Caspofungin for Treatment of Invasive Aspergillosis in Patients Refractory to or Intolerant of Conventional Antifungal Therapy

Cited by 625 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Choosing Among Antifungal Agents: Polyenes, Azoles, and Echinocandins;2024 Nelson’s Pediatric Antimicrobial Therapy;2024-02-14

2. Preferred Therapy for Specific Fungal Pathogens;2024 Nelson’s Pediatric Antimicrobial Therapy;2024-02-14

3. Therapeutic drug monitoring of liposomal amphotericin B in children. Are we there yet? A systematic review;Journal of Antimicrobial Chemotherapy;2024-01-22

4. Acute Invasive Pulmonary Aspergillosis: Clinical Presentation and Treatment;Seminars in Respiratory and Critical Care Medicine;2024-01-11

5. Update on therapeutic approaches for invasive fungal infections in adults;Therapeutic Advances in Infectious Disease;2024-01